AI on the JVM accelerates: New frameworks like Embabel, Koog, Spring AI, and LangChain4j drive rapid adoption of AI-native and AI-assisted development in Java. Java 25 anchors a modern baseline: The ...

Johnson Controls delivered a strong Q4, surpassing expectations and prompting a rating upgrade from Hold to Buy with a $125 target price. JCI's transformation, backlog growth, margin improvement, and ...

The success of political slogans often brings forth intellectual defenders, even when the slogans themselves lack merit. Calls to “freeze the rent” and cap electricity prices before this month’s ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

The changes would make it easier for American firms to obtain key minerals, delivering on what the White House said the two countries had agreed to at last month’s summit. By Keith Bradsher Reporting ...

Excavated with colonial labor and shipped to the Netherlands, the famous fossil is being repatriated to Indonesia along with 28,000 other fossils. The skull cap of 'Java Man' was discovered by Eugène ...

Meta is adding parental controls for kids’ interactions with artificial intelligence chatbots — including the ability to turn off one-on-one chats with AI characters altogether — beginning early next ...

It’s time to fight against the powers that be in Hades 2. The controls and keybindings for the sequel are much the same as they were in the original, but the addition of charged moves adds a new layer ...

Albion Online has expanded the Crystal Weapons series with some new complementary offhand items. The latest update also adjusts the Mists, and addresses the issue caused by those who’d run into ...

Johnson Controls, the 140-year-old leader in building technologies has thoroughly modernized such that it is able to drive remarkable value with the use of technology. With annual revenues exceeding ...

For decades, America’s drug-price debate has centered on a fundamental tension: How do policymakers encourage expensive research and development, while ensuring that companies keep final prices ...